查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967669

基因递送技术市场－全球产业规模、份额、趋势、机会与预测：按模式、方法、应用、地区和竞争格局划分，2021-2031年

Gene Delivery Technologies Market - Global Industry Size, Share, Trends,Opportunity and Forecast, Segmented By Mode, By Method, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球基因转殖技术市场预计将从 2025 年的 34.1 亿美元成长到 2031 年的 60.1 亿美元，复合年增长率为 9.91%。

此领域涵盖病毒和非病毒载体系统，旨在将治疗性遗传物质导入宿主细胞，用于治疗慢性病和遗传性疾病。主要成长动力包括全球可治疗遗传性疾病发病率的上升以及大量资金涌入生物技术研发领域。此外，建立支持性法规结构以加速新药核准是行业增长的基石。

市场概览
预测期 2027-2031
市场规模：2025年 34.1亿美元
市场规模：2031年 60.1亿美元
复合年增长率：2026-2031年 9.91%
成长最快的细分市场 生物
最大的市场 北美洲

近期发展数据凸显了该领域的蓬勃发展。正如美国基因与细胞治疗学会2024年所指出的，全球治疗研发管线包含超过4000种治疗方法，其中基因疗法占近50%。儘管发展势头强劲，但该行业仍面临着与大规模载体生产的高度复杂性和高成本相关的重大挑战。这些生产难题仍然是阻碍市场渗透和限制商业性扩充性的主要障碍。

市场驱动因素

病毒和非病毒载体系统的重大技术突破正推动市场发展，将实验性候选药物转化为可商业化的治疗药物。该领域已进入关键的成熟阶段，从早期概念验证发展到获得监管部门核准，涵盖了诸如先进的腺结合病毒载体和基于CRISPR的基因编辑技术等复杂疗法。这一发展进程伴随着市场活动的空前繁荣。再生医学联盟在2024年1月报告称，美国FDA在2023年核准了7种基因疗法，创下年度批准总数新高。这些核准凸显了新一代递送平台的有效性，并推动了对新型可程式设计疗法的持续投资。例如，Arsenal Biosciences在2024年9月完成了3.25亿美元的C资金筹措，用于推进其针对固态肿瘤的可程式设计细胞疗法计画。

此外，日益增多的策略联盟和产业合作正成为推动成长的关键催化剂，使企业能够应对高昂的研发成本和生产挑战。领导企业正积极寻求併购和授权协议，以整合其专有的衣壳技术，加速临床研发管线，而无需承担全部内部研发负担。此类合作对于扩大生产规模和获得全球商业化所需的专业递送机制至关重要。一个显着的例子是，Astellas来製药于2024年10月与Aviad Bio签署了一项价值高达21.8亿美元的独家选择权和授权合约协议，共同开髮用于治疗额额颞叶型失智症的基因疗法。

市场挑战

大规模载体生产固有的高昂成本和复杂性是全球基因递送技术市场的主要阻碍因素。与传统药物生产不同，病毒载体的製备需要复杂的生物学过程，这些过程本身就难以标准化和规模化。这种生产规模上的限制在供应链中造成了严重的瓶颈，导致销货成本（COGS）增加。由于製造商难以有效率地进行商业规模生产，由此产生的经济负担往往转嫁到医疗保健系统，导致保险覆盖范围有限和市场渗透率下降。

这种困难在近期核准治疗方法的定价策略中得到了量化体现。根据再生医学联盟2024年的数据，单剂基因疗法的批发采购成本已上涨至约310万美元。如此高昂的价格，主要源自于载体生产所需的大量资金投入，这极大地限制了能够获得这些改变人生的治疗方法的患者群体。因此，由于高昂的生产成本阻碍了这些治疗方法的广泛应用，市场的全部商业性潜力尚未充分发挥。

市场趋势

将人工智慧 (AI) 整合到载体设计中，正在彻底改变基因递送方法的发现和改进。透过利用机器学习演算法，研究人员正摆脱传统的经验筛检方法，转而采用计算设计来建构合成衣壳，从而提高组织亲和性并降低免疫抗原性。这种以数据为中心的策略能够模拟复杂的生物交互作用，显着加快筛选出有前景的候选载体的速度，这些候选载体既能优化转运效率，又能规避现有的免疫反应。主要行业参与者的战略充分体现了这项技术进步的重要性。例如，《Inc.》杂誌在2025年5月报道称，Moderna公司已在其营运中部署了3000多个客製化AI模型，以增强mRNA药物及其递送系统的设计和开发。

同时，脂质奈米颗粒（LNP）作为一种非病毒载体，正迅速成为市场上的主流，用于扩大治疗药物的有效载荷。儘管病毒载体先前占据主导地位，但LNP卓越的扩充性、安全性以及多功能性正推动其应用范围从疫苗扩展到复杂的蛋白质替代疗法和基因编辑疗法。领先的製药公司正积极建立自己的LNP平台，以确保其基因治疗产品线拥有强大的递送能力，从而避免病毒载体常见的生产瓶颈。近期一些高价值交易清晰地展现了这种策略整合的趋势，例如艾伯维（AbbVie）计划于2025年6月以高达21亿美元的价格收购Capstan Therapeutics，这将整合用于体内细胞重编程的靶向脂质奈米颗粒技术。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第4章 顾客の声

第五章：全球基因递送技术市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按方式（生物、化学、物理）
    • 依方法（体外、体内、体外）
    • 用途别（遗伝子治疗、细胞治疗、ワクチン、调査）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美基因递送技术市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲基因传递技术市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区基因传递技术市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲基因传递技术市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲基因递送技术市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球基因传递技术市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Thermo Fisher Scientific, Inc
  • Promega Corporation
  • Qiagen NV
  • Horizon Discovery Ltd.
  • OriGene Technologies, Inc.
  • Oxford Biomedica Plc
  • SignaGen Laboratories
  • Takara Bio Inc.
  • Bio-Rad Laboratories, Inc.
  • System Biosciences, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23873

The Global Gene Delivery Technologies Market is projected to expand from a valuation of USD 3.41 Billion in 2025 to reach USD 6.01 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 9.91%. This sector comprises both viral and non-viral vector systems engineered to convey therapeutic genetic materials into host cells to treat chronic diseases and genetic disorders. Primary growth stimulants include the rising global incidence of treatable genetic conditions and a substantial influx of capital investment into biotechnological research and development. Additionally, the establishment of supportive regulatory frameworks designed to accelerate the approval of novel therapeutic agents acts as a fundamental pillar for industry growth.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.41 Billion
Market Size 2031USD 6.01 Billion
CAGR 2026-20319.91%
Fastest Growing SegmentBiological
Largest MarketNorth America

Recent developmental data highlights the sector's vitality; as noted by the American Society of Gene & Cell Therapy in 2024, the global therapy pipeline encompassed more than 4,000 treatments, with gene therapies accounting for nearly 50% of these candidates. Despite this progressive momentum, the industry faces significant hurdles related to the high complexity and expense of large-scale vector manufacturing. These production challenges remain a substantial obstacle that threatens to hinder widespread market adoption and limit commercial scalability.

Market Driver

Significant technical breakthroughs in viral and non-viral vector systems are driving the market forward by transforming experimental candidates into commercially available treatments. The sector has reached a crucial stage of maturity, progressing from initial proof-of-concept phases to achieving regulatory success for complex modalities like advanced adeno-associated virus vectors and CRISPR-based editing. This evolution is highlighted by a record surge in market activity; the Alliance for Regenerative Medicine reported in January 2024 that the US FDA approved seven gene therapies in 2023, marking the highest annual total to date. These approvals confirm the effectiveness of next-generation delivery platforms and encourage sustained investment in novel programmable therapies, as evidenced by Arsenal Biosciences raising $325 million in Series C financing in September 2024 to advance its programmable cell therapy programs for solid tumors.

Furthermore, a rise in strategic partnerships and industry collaborations is serving as a key catalyst for growth, allowing firms to manage high development expenses and manufacturing difficulties. Biopharmaceutical leaders are actively seeking mergers and licensing deals to incorporate proprietary capsid technologies and expedite clinical pipelines without bearing the entire weight of internal research. Such alliances are critical for scaling up production and obtaining the specialized delivery mechanisms necessary for global commercialization. A notable example of this trend occurred in October 2024, when Astellas Pharma finalized an exclusive option and license agreement with AviadoBio, potentially worth up to $2.18 billion, to develop gene therapies targeting frontotemporal dementia.

Market Challenge

The substantial cost and complexity inherent in large-scale vector manufacturing present a major constraint on the Global Gene Delivery Technologies Market. In contrast to traditional pharmaceutical manufacturing, the creation of viral vectors requires intricate biological processes that are intrinsically challenging to standardize and scale. This limitation in manufacturing scalability creates significant supply chain bottlenecks and leads to a higher Cost of Goods Sold (COGS). As manufacturers encounter difficulties in efficiently producing commercial quantities, the resulting financial burden is frequently transferred to the healthcare system, resulting in restricted insurance coverage and diminished market penetration.

This difficulty is quantitatively evident in the pricing strategies for recently authorized treatments. Data from the Alliance for Regenerative Medicine in 2024 indicates that the wholesale acquisition cost for a single gene therapy treatment has climbed to approximately $3.1 million. Such elevated price points, driven by the capital-intensive requirements of vector production, severely limit the patient population capable of accessing these life-changing therapies. Consequently, the market's full commercial potential remains unrealized, as prohibitive manufacturing costs hinder the ability of these therapies to reach a wider audience.

Market Trends

The incorporation of Artificial Intelligence into vector design is revolutionizing the discovery and refinement of gene delivery vehicles. By utilizing machine learning algorithms, researchers are shifting away from traditional empirical screening methods toward the computational engineering of synthetic capsids that offer improved tissue tropism and lowered immunogenicity. This data-centric strategy enables the simulation of intricate biological interactions, vastly speeding up the identification of viable candidates capable of evading pre-existing immunity while optimizing transduction efficiency. The significance of this technological evolution is demonstrated by the strategies of key industry players; for instance, Inc. Magazine reported in May 2025 that Moderna has implemented over 3,000 customized artificial intelligence models across its operations to enhance the design and development of mRNA medicines and their delivery systems.

Concurrently, the market is witnessing an accelerated shift toward Lipid Nanoparticles (LNPs) as the preferred non-viral delivery method for an expanding array of therapeutic payloads. Although viral vectors have traditionally held dominance, the superior scalability, safety profile, and versatility of LNPs are fueling their growth beyond vaccine applications into complex protein replacement and gene editing therapies. Leading pharmaceutical companies are aggressively acquiring proprietary LNP platforms to ensure robust delivery capabilities for their genetic medicine pipelines, thereby circumventing the manufacturing bottlenecks often linked to viral vectors. This trend of strategic consolidation is exemplified by recent high-value deals, such as AbbVie's agreement in June 2025 to acquire Capstan Therapeutics for up to $2.1 billion to integrate its targeted lipid nanoparticle technology for in vivo cell reprogramming.

Key Market Players

  • Thermo Fisher Scientific, Inc
  • Promega Corporation
  • Qiagen N.V.
  • Horizon Discovery Ltd.
  • OriGene Technologies, Inc.
  • Oxford Biomedica Plc
  • SignaGen Laboratories
  • Takara Bio Inc.
  • Bio-Rad Laboratories, Inc.
  • System Biosciences, LLC

Report Scope

In this report, the Global Gene Delivery Technologies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Delivery Technologies Market, By Mode

  • Biological
  • Chemical
  • Physical

Gene Delivery Technologies Market, By Method

  • Ex vivo
  • In vivo
  • In vitro

Gene Delivery Technologies Market, By Application

  • Gene Therapy
  • Cell Therapy
  • Vaccines
  • Research

Gene Delivery Technologies Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Delivery Technologies Market.

Available Customizations:

Global Gene Delivery Technologies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Delivery Technologies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Mode (Biological, Chemical, Physical)
    • 5.2.2. By Method (Ex vivo, In vivo, In vitro)
    • 5.2.3. By Application (Gene Therapy, Cell Therapy, Vaccines, Research)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Gene Delivery Technologies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Mode
    • 6.2.2. By Method
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Delivery Technologies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Mode
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Gene Delivery Technologies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Mode
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Gene Delivery Technologies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Mode
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By Application

7. Europe Gene Delivery Technologies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Mode
    • 7.2.2. By Method
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gene Delivery Technologies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Mode
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Application
    • 7.3.2. France Gene Delivery Technologies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Mode
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Gene Delivery Technologies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Mode
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Gene Delivery Technologies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Mode
        • 7.3.4.2.2. By Method
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Gene Delivery Technologies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Mode
        • 7.3.5.2.2. By Method
        • 7.3.5.2.3. By Application

8. Asia Pacific Gene Delivery Technologies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Mode
    • 8.2.2. By Method
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Delivery Technologies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Mode
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Application
    • 8.3.2. India Gene Delivery Technologies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Mode
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Gene Delivery Technologies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Mode
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Gene Delivery Technologies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Mode
        • 8.3.4.2.2. By Method
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Gene Delivery Technologies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Mode
        • 8.3.5.2.2. By Method
        • 8.3.5.2.3. By Application

9. Middle East & Africa Gene Delivery Technologies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Mode
    • 9.2.2. By Method
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gene Delivery Technologies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Mode
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Gene Delivery Technologies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Mode
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Gene Delivery Technologies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Mode
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Application

10. South America Gene Delivery Technologies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Mode
    • 10.2.2. By Method
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Delivery Technologies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Mode
        • 10.3.1.2.2. By Method
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Gene Delivery Technologies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Mode
        • 10.3.2.2.2. By Method
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Gene Delivery Technologies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Mode
        • 10.3.3.2.2. By Method
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Delivery Technologies Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Promega Corporation
  • 15.3. Qiagen N.V.
  • 15.4. Horizon Discovery Ltd.
  • 15.5. OriGene Technologies, Inc.
  • 15.6. Oxford Biomedica Plc
  • 15.7. SignaGen Laboratories
  • 15.8. Takara Bio Inc.
  • 15.9. Bio-Rad Laboratories, Inc.
  • 15.10. System Biosciences, LLC

16. Strategic Recommendations

17. About Us & Disclaimer